![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myriad Pharmaceuticals Presents Data From Nampt Inhibitor Program at AACR 101st Annual Meeting
20 avr. 2010 14h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, April 20, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of preclinical data characterizing MPI-0486348, the lead compound in the...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
19 avr. 2010 09h05 HE
|
Myrexis, Inc.
SALT LAKE CITY, April 19, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the termination, effective as of Friday, April 16, 2010, of its merger agreement with...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
12 avr. 2010 09h32 HE
|
Myrexis, Inc.
SALT LAKE CITY, April 12, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc (Nasdaq:MYRX) today announced that it has received a notice from Javelin Pharmaceuticals, Inc. (NYSE Amex:JAV) of its...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myriad Pharmaceuticals, Inc. Sets Date for Special Stockholder Meeting to Approve Merger with Javelin Pharmaceuticals, Inc.
15 mars 2010 09h15 HE
|
Myrexis, Inc.
SALT LAKE CITY, March 15, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX), announced today that a registration statement on Form S-4 relating to the proposed merger with Javelin...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myriad Pharmaceuticals Reports Second Quarter FY' 2010 Financial Results
16 févr. 2010 16h15 HE
|
Myrexis, Inc.
SALT LAKE CITY, Feb. 16, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its second fiscal quarter ended December 31, 2009.
"We are pleased...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myriad Pharmaceuticals to Present at BIO CEO & Investor Conference on February 8th
03 févr. 2010 09h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Feb. 3, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
FDA Accepts Javelin Pharmaceuticals' Submission and Files New Drug Application for Dyloject(TM)
02 févr. 2010 09h09 HE
|
Myrexis, Inc.
SALT LAKE CITY, Feb. 2, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted Javelin Pharmaceuticals’...
![Myrexis, Inc. Logo](http://www.globenewswire.com/fr/Attachment/LogoDisplay/218223?filename=218223.jpg&size=2)
Myriad Pharmaceuticals to Acquire Javelin Pharmaceuticals
18 déc. 2009 08h15 HE
|
Myrexis, Inc.
Creates Pipeline With Potential Near-Term Product Launch of
Dyloject(TM) and Portfolio of Early-, Mid- and Late-Stage
Drug Candidates in Cancer, HIV and Pain
...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myriad Pharmaceuticals Initiates Phase 2b Study of MPC-4326 in a Genetically-Identified Responder Population
01 déc. 2009 08h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Dec. 1, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the initiation of a Phase 2b study of MPC-4326, a first-in-class, small molecule inhibitor of...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myriad Pharmaceuticals Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
23 nov. 2009 21h51 HE
|
Myrexis, Inc.
SALT LAKE CITY, Nov. 23, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) announced today that Adrian Hobden, President and CEO, is scheduled to present an overview of the Company at...